Speaker(s): 

John Horne, MD, Resident, Geisinger - has nothing to disclose.

Jeffrey Wojciechowski, DO, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Staff Physician, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the principles of cfDNA testing and the markers used to screen for colorectal cancer.
• Compare the performance of cfDNA blood-based colorectal cancer tests to current commercially available screening tests.
• Discussion of the discovery of antigens associated with MN (membranous nephropathy).
• Discuss novel classification of MN (membranous nephropathy) based on antigen and disease. 

Disclosure of Relevant Financial Relationships without Commercial Interests:

The Planning Committee consisting of Zachary Hoffer, MD PhD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure:  None.

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:  None.